Efficacy and safety of the Brazilian vaccine against hepatitis B in newborns;Eficácia e segurança da vacina brasileira contra hepatite B em recém-nascidos

Revista de Saude Publica

Volumn 43, Issue 6, 2009, Pages 1014-1020

  Luna, Expedito José de Albuquerque ^a   de Moraes, José Cássio ^b   Silveira, Lygia ^b   Salinas, Hilda Souza Neves ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^c Hospital Geral de Guarulhos   (Brazil)

Author keywords

Clinical trial; Efficacy; Hepatitis B; Hepatitis B vaccines; Infant; Newborn; Prevention and control

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ARTICLE; BRAZIL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGY; MALE; NEWBORN; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL;

BRAZIL; FEMALE; HEPATITIS B VACCINES; HUMANS; INFANT, NEWBORN; MALE; THERAPEUTIC EQUIVALENCY; VACCINES, SYNTHETIC;

EID: 77951891679     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-89102009005000071     Document Type: Article

References (11)

1. Costa AA, Inenami M, Juarez E, Llacen PD, Raw I. Preliminary Report of the Use of a Recombinant Yeast-derived Hepatitis B Vaccine Manufactured by Instituto Butantan. Rev Inst Med Trop Sao Paulo. 1997;39(1):39-42. DOI:10.1590/S0036-46651997000100008
2. Desombere I, Hanser P, Rossau R, Paradijs J, Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol. 1995;154(2):520-9.
3. Figueiredo GM. Breve histórico da emergência da hepatite B como problema de saúde pública. J Bras AIDS. 2007;8(1):8-13.
4. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy and indications for immunization. Curr Clin Top Infect Dis. 1992;12:283-308.
5. Ioshimoto LM, Rissato ML, Bonilha VSJ, Miyaki C, Raw I, Granovsky N. Safety and immuunogenicity of hepatitis B vaccine Butang in adults. Rev Inst Med Trop Sao Paulo. 1999;41(3):191-3 DOI:10.1590/S003646651999000300011
6. Martins RM, Bensabath G, Arraes LC, Oliveira ML, Miguel JC, Barbosa GG, et al. Multicenter Study on the Immunogenicity and Safety of Two Recombinant Vaccines Against Hepatitis B. Mem Inst Oswaldo Cruz. 2004;99(8):865-71. DOI:10.1590/S007402762004000800014
7. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1-31.
8. Motta MSF, Mussi-Pinhata MM, Jorge SM, Yoshida CFT, Souza CBS. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine. 2002;20(11-12):1557-62. DOI:10.1016/S0264-410X(01)00493-5
9. Moraes JC, Luna EJA, Grimaldi RA. Imunogenicidade da vacina brasileira contra hepatite B em adultos. Rev Saude Publica.2010;44(2).No prelo.
10. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW, CONSORT Group. Reporting of Noninferiority and Equivalence Randomized Trials, an Extension of the CONSORT statement. JAMA. 2006;295(10):115260. DOI:10.1001/jama.295.10.1152
11. World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. Geneva; 2004. (WHO Technical Report series, 924).